ChemoTox Report™ – Breast Cancer
Genetic Screening to Help Identify Chemotherapy Toxicity Risk
$495 + HST
Chemotherapy can be highly effective in treating breast cancer, but each person's body processes medications differently. Genetic differences can affect the enzymes and pathways involved in breaking down certain chemotherapy medications, which may influence medication exposure and the risk of serious side effects.
ChemoTox Report™ – Breast Cancer is a pharmacogenomic screening designed to identify genetic factors that may affect how your body processes selected breast cancer medications. The results provide your oncology team with additional information that may help support safer, more personalized treatment decisions.
Testing can be completed before chemotherapy begins or during treatment. Understanding your genetic profile may help your healthcare provider identify potential medication toxicity risks and determine whether additional precautions, monitoring, dose considerations, or treatment adjustments may be appropriate.
Why Your Genetics Matter
Your body relies on specific enzymes to metabolize and clear medications. Genetic variations can reduce the activity of some of these enzymes, causing certain medications to remain in the body longer or reach higher concentrations than expected.
One important example involves fluoropyrimidine chemotherapy medications such as capecitabine and 5-Fluorouracil (5-FU). The DPYD gene helps determine the activity of the DPD enzyme, which is responsible for breaking down most fluorouracil in the body. Certain DPYD genetic variants can significantly reduce DPD activity and increase the risk of serious or potentially life-threatening toxicity.
Identifying clinically relevant genetic variations before treatment gives your oncology team additional information that can be considered alongside your diagnosis, treatment plan, medical history, laboratory results, and other clinical factors.
What's Included
Your ChemoTox Report™ – Breast Cancer includes:
- Multi-gene pharmacogenomic analysis focused on chemotherapy metabolism and toxicity risk
- Analysis of clinically relevant genetic variants associated with selected breast cancer medications
- Evaluation of genetic factors that may influence medication metabolism, exposure, and toxicity
- Professional clinical report designed for review by your oncologist or healthcare provider
- Medical review by a clinical MD/PhD
- Personalized genetic information that may help your healthcare team make more informed treatment decisions
Supporting Safer, More Personalized Cancer Treatment
Your oncologist selects chemotherapy based on the characteristics of your cancer and your individual treatment needs. ChemoTox Report™ provides another layer of information by examining genetic factors that may influence how your body processes certain chemotherapy medications.
The goal is to give you and your oncology team additional information before and during treatment so that potential genetic risk factors can be considered when making treatment decisions.
When Should You Get Tested?
Ideally, pharmacogenomic screening can be completed before chemotherapy begins, giving your healthcare provider an opportunity to review your results as part of your treatment planning.
If you have already started treatment, genetic information may still provide useful information about how your body processes certain medications and can be reviewed by your healthcare provider during your treatment journey.
At-Home DNA Collection
ChemoTox Report™ begins with a simple, non-invasive DNA sample that can be collected at home. Your sample is then sent to the laboratory for genetic analysis.
Once the analysis is complete, your results are interpreted and presented in a professional clinical report designed to be reviewed with your healthcare provider.
Laboratory & Medical Review
ChemoTox Report™ is medically reviewed by a clinical MD/PhD. Genetic testing is processed through PGX Lab Solutions, a College of American Pathologists (CAP) accredited laboratory with ISO 9001 and ISO 27001 certifications.
Please note: ChemoTox Report™ does not diagnose cancer, determine whether chemotherapy is required, or replace the clinical judgment of your oncologist or healthcare provider. Treatment and dosing decisions should always be made by your healthcare team.
English
Français